[Molecular-targeted therapy and its impact on post-transplant immunity]

Over the past few decades, the advancements in the area of molecular-targeted therapy have revolutionized the treatment of hematological malignancies, thereby altering the role of allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, allo-HSCT continues to play an essential role in the treatment of hematological malignancies because the cure is rare by targeted therapy alone. In the modern era, the incorporation of molecular-targeted therapy, including chemotherapy and allo-HSCT, into the conventional therapy is the key to attaining therapeutic success. In particular, it is imperative to comprehend the precise immune impact of molecular-targeted therapy on GVHD and GVL besides the direct effect while using the therapy before and/or after allo-HSCT.